Key result
Resource-adapted ECMO-based platform maintains ex vivo heart perfusion and stabilizes metabolism for ~6 hours.
Why the study?
Normothermic ex vivo heart perfusion may reduce cold ischemic injury in heart transplantation, but the cost, complexity, and logistical requirements of commercial systems limit implementation outside well-resourced programs.
Does a resource-adapted ECMO-based ex vivo heart perfusion platform support metabolic stabilization and ex situ perfusion in explanted human hearts?
Does a resource-adapted ECMO-based ex vivo heart perfusion platform support metabolic stabilization and ex situ perfusion in explanted human hearts?
This three-case feasibility study demonstrates that a resource-adapted ECMO-based platform can maintain normothermic ex situ perfusion and achieve metabolic stabilization of explanted human hearts for 4–6 hours, offering a potential low-cost alternative for organ preservation in resource-limited settings.
Answers are grounded in this paper and cite their sources.
Demonstrates feasibility of compact ECMO perfusion in explanted hearts; leaves open clinical utility for donor preservation.
Background Cold ischemic injury remains a major limitation in heart transplantation, particularly when donor organs must be transported over long distances. Normothermic ex vivo heart perfusion may reduce ischemic damage and enable functional assessment of the organ before implantation; however, the cost, system complexity, and logistical requirements of commercial systems limit broad implementation outside well-resourced transplant programs. Methods A compact, resource-adapted ex vivo heart perfusion device (Ukrainian patent UA 156631 U) was evaluated during normothermic perfusion of three explanted human hearts at 34°C. Perfusion targets included aortic inflow of 700–800 mL/min, with epinephrine titrated as needed. Arterial perfusate was sampled at baseline and hourly to assess acid-base status, electrolytes, glucose, lactate, hemoglobin, and myocardial injury markers. Heart weight was recorded before and after perfusion, and myocardial tissue underwent semi-quantitative histopathologic evaluation. Given the exploratory design, results were summarized descriptively as individual case values over time. Results Across all three experiments, normothermic ex vivo perfusion was associated with progressive metabolic stabilization. pH increased from baseline acidosis (6.95–7.00) to near-physiologic values by 180 minutes (7.30–7.33). Uncorrected lactate values declined to <5 mmol/L by 180 minutes in all cases, while glucose decreased steadily and electrolytes remained within narrow ranges. Myocardial injury markers increased after reperfusion, with the steepest rise during the first hour, followed by slower increases thereafter. Heart weight increased modestly (3.53%–4.58%), consistent with mild edema, and histopathology showed predominantly mild-to-moderate changes. No air embolism or device-related mechanical complications were observed. Conclusion In this early three-case feasibility study, a resource-adapted ECMO-based platform successfully maintained aortic inflow and supported ex situ perfusion of explanted human hearts for 4–6 hours, while enabling continuous metabolic assessment. These findings demonstrate the technical feasibility of the platform and support its potential as an accessible alternative for prolonged normothermic heart perfusion in resource-limited settings. Further controlled studies incorporating direct aortic root pressure monitoring, standardized functional assessment, and transplantation endpoints are warranted to validate its performance and clinical applicability.
No takes yet. Share an insight, caveat, or question.
Sudakevych et al. (2026) studied Explanted human donor hearts for transplantation (n=3). Resource-adapted ECMO-based normothermic ex vivo heart perfusion device (Ukrainian patent UA 156631 U) was evaluated on Technical feasibility and metabolic stabilization (acid-base status, lactate, electrolytes, glucose, myocardial injury markers, heart weight change, and histopathology). The resource-adapted ECMO-based ex vivo platform maintained perfusion for 4–6 hours in 3 hearts, normalizing pH and reducing lactate to <5 mmol/L by 180 minutes.
Synapse has enriched 10 related papers. Consider them for comparative context: